CUHK outlines development plans for Huntington’s peptide with FDA orphan designation

The Chinese University of Hong Kong announced September 23 that it and its spin-off Rare Power are advancing an experimental Huntington’s disease peptide toward human testing. The candidate, RP001v63, has FDA orphan drug designation, providing development incentives for a program that remains preclinical.

The chronology matters: FDA records date the designation to August 3, 2026. This week’s university announcement describes the development program; it does not represent a new September approval. The agency’s database identifies Rare Power as sponsor and explicitly lists the product as unapproved for the designated indication.

What the designation changes

FDA orphan designation supports development of products for rare diseases. Qualifying incentives include tax credits for clinical trials, exemption from user fees and potentially seven years of market exclusivity after approval. Those provisions can influence whether a small development program attracts the resources needed to continue.

Designation and marketing approval are separate processes. FDA says rare-disease medicines undergo the same rigorous scientific review required of other drugs. The designation therefore establishes a regulatory development status without demonstrating that this peptide improves symptoms, preserves independence or extends survival.

The database describes the candidate by its molecular target: a 21-amino-acid peptide directed at expanded CAG-repeat RNA. That entry confirms the designated product and disease, but supplies no clinical trial outcomes. Readers should not interpret inclusion in an FDA database as permission to market a treatment.

An RNA-focused research approach

Huntington’s disease is an inherited, progressive brain disorder involving movement, cognition and emotional health. The most common adult-onset form generally appears in the thirties or forties. As illness advances, people can develop difficulties with walking, speaking, swallowing and reasoning, making preservation of everyday function a central concern.

The underlying genetic change involves excessive repetition of a DNA sequence in the HTT gene. This alters huntingtin, a protein important to nerve cells. One altered copy of the gene can cause the disorder, which explains its dominant inheritance pattern.

According to CUHK, RP001v63 is designed to recognize the folded structure of expanded repeat RNA. The university describes laboratory work using patient-derived neurons. That is a cell model, not treatment of patients, and the announcement provides no numerical efficacy results, sample sizes or detailed controlled-study methods for assessing the reported activity.

The proposed mechanism is consequently a research rationale. It does not establish that targeting this RNA will change the course of Huntington’s disease in people.

The next evidence threshold

CUHK says manufacturing development and safety work, including longer-term toxicology in large animals, are among the next steps. Its stated goal is to begin a first-in-human study within one to two years. That is a development target rather than a confirmed trial opening or a forecast of approval.

For patients and clinicians, the distinction between laboratory activity and clinical benefit remains decisive. A future program would need evidence addressing human safety and whether any biological effect translates into outcomes that matter to patients. No human population, randomized comparison or clinical endpoint result is reported in this update.

The practical significance is a documented development pathway for an experimental peptide aimed at a serious neurodegenerative disease. Whether the program can progress into human trials—and ultimately preserve movement, cognition or daily function—remains unanswered.